Peptide Based Metabolic Disorders Therapeutics Market
Peptide Based Metabolic Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022
There are several ongoing research activities and technological developments in accordance with medical research activities which focus on treatment of various ailments.
Peptide therapeutics are used to treat several of these ailments, of which metabolic disorders are one type. Peptides possess good stability, efficacy, safety, and moreover, they are small in size, and hence can be easily synchronized. These advantages fuel the growth of the global peptide based metabolic disorders therapeutics market.
To support the growth, factors such as technological advancements and increased funding in healthcare, and the impressive business growth of biotech and pharmaceutical companies, have spurred the adoption of the peptides used to treat metabolic disorders.
Such disorders have risen, and this has called for a rapid development of therapies based on peptides to treat such disorders. North America is anticipated to show higher attractiveness in the global peptide based metabolic disorders therapeutics market.
A metabolic disorder is a disorder which can occur due to alterations in the normal metabolic processes in the body caused by abnormal chemical reactions take place within.
Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability. Due to their broad range of mechanisms and activities, they can be used in the treatment of metabolic disorders.
According to Fact.MR’s research report on the global peptide based metabolic disorders therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value more than US$ 8 Bn.
North America Domination in the Peptide Based Metabolic Disorders Therapeutics
With respect to the global peptide based metabolic disorders therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share.
In terms of revenues, North America is poised to grow at a higher growth rate, registering a CAGR of 10.6% throughout the period of forecast of 2017 to 2022.
This region is expected to show the highest market attractiveness index, and is the most lucrative region for the growth of the global peptide based metabolic disorders therapeutics market.
Middle East and Africa (MEA) and Latin America regions will show slower growth rate as compared to North America, as well as a comparatively low market revenue share
APEJ Shows a Similar Growth Rate
The Asia-Pacific excluding Japan (APEJ) region had shown rapid growth in the past with respect to global peptide based metabolic disorders therapeutics market, and is poised to reflect a higher growth rate, as fast as North America.
APEJ will register a CAGR of 10.5% during the forecast period. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies.
Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods & technologies to better the health of the patients and enhance treatment outcomes. Europe region, following APEJ region, also reflects itself as a positive platform for the growth of the global peptide based metabolic disorders therapeutics market.
Liraglutide Dominates the Drug Class Category
The liraglutide segment by drug class reflects a higher market share by revenue and dominates the global market by drug class. The market share of this segment is more than two and a half times than that of the exenatide segment as of 2017.
However, it is anticipated that this segment will lose BPS by the end of 2022. The growth of liraglutide segment is slow as compared to the growth rates of the exenatide and others segments throughout the period of forecast.
Avail customized purchase options for your needs
Exenatide and Others Segments Have a Tie
The exenatide and others segments by drug class show similar growth rate and hence can be said to congruently move along during the period of forecast.
However, the exenatide segment enjoys a higher market share than the others segment, more than three times than that of the others segment during 2017 and this trend is expected to run its course throughout the period of forecast. Both these segments are expected to show a gain in the BPS by the end of 2022.
Hospital Pharmacies Segment Shows Supremacy, Online Pharmacy Shows Growth
The hospital pharmacies segment by distribution channel reflect a higher market share by revenue and a higher growth rate throughout the period of forecast.
However, the online pharmacies segment shows even higher growth rate as compared to hospital pharmacies segment, and is expected to register a CAGR of 11.8% during the period of forecast. But the market share of this segment is less; hospital pharmacies segment enjoys a market share more than three times than that of online pharmacies segment.
The online pharmacies segment is expected to enjoy a gain in the BPS by the end of 2022. On the other hand, the retail pharmacies segment shows moderate growth rate, yet higher than that of the hospital pharmacies segment and a market share more than double than that of the online pharmacies segment as of 2017.
An Adaptive Approach to Modern-day Research Needs
The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include
- AstraZeneca PLC
- Teva Pharmaceutical Industries Ltd.
- PolyPeptide Group
- Novo Nordisk A/S
- Merck & Co., Inc.
- Ipsen S.A, Eli Lilly
- CordenPharma International
- Bachem Holding AG.
(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.